InnoPharmax Inc. (TPEX:4172)
Taiwan · Delayed Price · Currency is TWD 11.15
-0.30 (-2.62%)
Aug 19, 2026, 1:52 PM CST
InnoPharmax Revenue
InnoPharmax had revenue of 22.35M TWD in the half year ending December 31, 2025, with 95.60% growth. This brings the company's revenue in the last twelve months to 67.47M, up 20.97% year-over-year. In the year 2025, InnoPharmax had annual revenue of 68.99M with 113.60% growth.
Revenue (ttm)
67.47M
Revenue Growth
+20.97%
P/S Ratio
17.70
Revenue / Employee
1.98M
Employees
34
Market Cap
1.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.99M | 36.69M | 113.60% |
| Dec 31, 2024 | 32.30M | -13.78M | -29.90% |
| Dec 31, 2023 | 46.07M | 16.94M | 58.15% |
| Dec 31, 2022 | 29.13M | -18.93M | -39.38% |
| Dec 31, 2021 | 48.06M | -88.82M | -64.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.40B |
| Prince Pharmaceutical | 1.06B |
| Excelsior Biopharma | 936.92M |
| Anxo Pharmaceutical | 878.88M |
| DV Biomed | 795.19M |
| GeneFerm Biotechnology | 664.94M |
| Winston Medical Supply | 632.80M |
| General Biologicals | 215.74M |